Prognostic factors in elderly patients with malignant pleural mesothelioma: Results of a multicenter survey

British Journal of Cancer

Volumn 111, Issue 2, 2014, Pages 220-226

  Ceresoli, G L ^a   Grosso, F ^b   Zucali, P A ^c   Mencoboni, M ^d   Pasello, G ^e   Ripa, C ^a   Degiovanni, D ^f   Simonelli, M ^c   Bruzzone, A ^d   Dipietrantonj, C ^g   Piccolini, E ^f   Beretta, G D ^a   Favaretto, A G ^e   Giordano, L ^c   Santoro, A ^c   Botta, M ^f  

^a Humanitas Gavazzeni Hospital   (Italy)

^b C Arrigo Children's Hospital   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d VILLA SCASSI HOSPITAL   (Italy)

^e VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^f Ospedale S Spirito Casale Monferrato   (Italy)

^g ASL Alessandria   (Italy)

Author keywords

Charlson Index; comorbidity; elderly; pemetrexed; pleural mesothelioma

Indexed keywords

ASBESTOS; CARBOPLATIN; GEMCITABINE; NAVELBINE; PEMETREXED;

AGED; CANCER CHEMOTHERAPY; CANCER SURGERY; CHARLSON COMORBIDITY INDEX; DISEASE CONTROL; ENVIRONMENTAL EXPOSURE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PERIPHERAL VASCULAR DISEASE; PLEURA MESOTHELIOMA; PLEURODESIS; PRIORITY JOURNAL; REVIEW; THORACOSCOPY;

AGE FACTORS; AGED; AGED, 80 AND OVER; COMORBIDITY; HUMANS; ITALY; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84904576554     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.312     Document Type: Review

References (41)

1. Brunello A, Sandri R, Extermann M (2009) Multidimensional geriatric evaluation for older cancer patients as a clinical and research tool. Cancer Treat Rev 35: 487-492.
2. Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15: 257-260.
3. Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella R, Mencoboni M (2008) Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 19: 370-373.
4. Ceresoli GL, Locati LD, Ferreri AJM, Cozzarini C, Passoni P, Melloni G, Zannini P, Bolognesi A, Villa E (2001) Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 34: 279-287.
5. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Soto-Parra HJ, Santoro A (2006) Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24: 1443-1448.
6. Ceresoli GL, Castagneto B, Zucali PA, Favaretto A, Mencoboni M, Grossi F, Cortinovis D, Del Conte G, Ceribelli A, Bearz A, salamina S, De Vincenzo F, Cappuzzo F, Marangolo M, Torri V, Santoro A (2008) Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 99: 51-56.
7. Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, Soto-Parra H, De Vincenzo F, Bruzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L, Santoro A (2013) Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer 109: 552-558.
8. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383.
9. Chen RC, Royce TJ, Extermann M, Reeve BB (2012) Impact of age and comorbidity on treatment and outcomes in elderly cancer patients. Semin Radiat Oncol 22: 265-271.
10. Clements M, Berry G, Shi J, Ware S, Yates D, Johnson A (2007) Projected mesothelioma incidence in men in New South Wales. Occup Environ Med 64: 747-752.
11. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16: 145-152.
12. Dale DC (2003) Poor prognosis in elderly patients with cancer: the role of bias and under-treatment. J Support Oncol 1(Suppl 2): 11-17.
13. de Magalhaes JP (2013) How ageing processes influence cancer. Nature Rev Cancer 13: 357-365.
14. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T (2011) Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 89: 716-724.
15. Diandini R, Takahashi K, Park EK, Jiang Y, Movahed M, Le GV, Lee LJ, Delgermaa V, Kim R (2013) Potential years of life lost (PYLL) caused by asbestos-related diseases in the world. Am J Ind Med 56: 993-1000.
16. Extermann M (2012) Integrating a geriatric evaluation in the clinical setting. Semin Radiat Oncol 22: 272-276.
17. Gatta G, Ciccolallo L, Kunkler I, Capocaccia R, Berrino F, Coleman MP, De Angelis R, Faivre J, Lutz JM, Martinez C, Moller T, Sankila R. and the EUROCARE Working Group (2006) Survival from rare cancer in adults: a population-based study. Lancet Oncol 7: 132-140.
18. Gervais R, Robinet G, Clément-Duchêne C, Denis F, El Kouri C, Martin P, Chouaki N, Bourayou N, Morère JF (2013) Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial. Lung Cancer 80: 185-190.
19. Gridelli C, Brodowicz T, Langer CJ, Peterson P, Islam M, Guba SC, Moore P, Visseren-Grul CM, Scagliotti G (2012) Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with non-squamous non-small-cell lung cancer. Clin Lung Cancer 13: 340-346.
20. Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S (2004) An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 4: 94-101.
21. Hall SF (2006) A user's guide to selecting a comorbidity index for clinical research. J Clin Epidemiol 59: 849-855.
22. Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC (2012) Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol 13: e437-e444.
23. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ (1998) Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113: 723-731.
24. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J (2005) The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 92: 587-593.
25. Kaplan EL, Meier P (1958) Nonparametric estimation of incomplete observations. J Am Stat Assoc 53: 457-481.
26. Kim YH, Hirabayashi M, Kosaka S, Nikaidoh J, Yamamoto Y, Shimada M, Toyazaki T, Nagai H, Sakamori Y, Mishima M (2013) Phase II study of pemetrexed as first-line treatment in elderly (X75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901. Cancer Chemother Pharmacol 71: 1445-1451.
27. Lichtman SM, Balducci L, Aapro M (2007) Geriatric oncology: a field coming of age. J Clin Oncol 25: 1821-1823.
28. Magnani C, Fubini B, Mirabelli D, Bertazzi PA, Bianchi C, Chellini E, Gennaro V, Marinaccio A, Menegozzo M, Merler E, Merletti F, Musti M, Pira E, Romanelli A, Terracini B, Zona A (2013) Pleural mesothelioma: epidemiological and public health issues. Report from the Second Italian Consensus Conference on Pleural Mesothelioma. Med Lav 104: 191-202.
29. Marinaccio A, Binazzi A, Marzio DD, Scarselli A, Verardo M, Mirabelli D, Gennaro V, Mensi C, Riboldi L, Merler E, Zotti RD, Romanelli A, Chellini E, Silvestri S, Pascucci C, Romeo E, Menegozzo S, Musti M, Cavone D, Cauzillo G, Tumino R, Nicita C, Melis M, Iavicoli S, ReNaM Working Group (2012) Pleural malignant mesothelioma epidemic: incidence, modalities of asbestos exposure and occupations involved from the Italian National Register. Int J Cancer 130: 2146-2154.
30. Myojin T, Azuma K, Okumura J, Uchiyama I (2012) Future trends of mesothelioma mortality in Japan based on a risk function. Ind Health 50: 197-204.
31. Pallis AG, Ring A, Fortpied C, Penninckx B, Van Nes MC, Wedding U, Vonminckwitz G, Johnson CD, Wyld L, Timmer-Bonte A, Bonnetain F, Repetto L, Aapro M, Luciani A, Wildiers H. European Organisation for Research and Treatment of Cancer Elderly Task Force (2011) EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumours. Ann Oncol 22: 1922-1926.
32. Park EK, Takahashi K, Hoshuyama T, Cheng TJ, Delgermaa V, Le GV, Sorahan T (2011) Global magnitude of reported and unreported mesothelioma. Environ Health Perspect 119: 514-518.
33. Price B, Ware A (2009) Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 39: 576-588.
34. Robinson BM (2012) Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg 1: 491-496.
35. Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108: 1122-1128.
36. Rusch VW, Giroux D (2012) Do we need a revised staging system for malignant pleural mesothelioma Analysis of the IASLC database. Ann Cardiothorac Surg 1: 438-448.
37. Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Pass H, Asamura H,Waller D, Edwards J, WederW, Hoffmann H, van Meerbeeck JP. IASLC Staging Committee (2012) Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 7: 1631-1639.
38. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17: 343-346.
39. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp Jr MM, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117: 54-65.
40. van der Bij S, Koffijberg H, Burgers JA, Baas P, van de Vijver MJ, de Mol BA, Moons KG (2012) Prognosis and prognostic factors of patients with mesothelioma: a population-based study. Br J Cancer 107: 161-164.
41. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzmeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644.